Transurethral Resection Of Bladder Tumor — Cost, Top Hospitals & Success Rates | MyMedicPlus

Transurethral resection of bladder tumor (TURBT) is an endoscopic surgical procedure used both to diagnose and treat bladder tumours. It is performed through the natural urinary passage (urethra) without any external incisions. A rigid or flexible resectoscope — a specialised telescopic instrument with a wire loop — is passed into the bladder under spinal or general anaesthesia, and the tumour tissue is excised using electrocautery.

TURBT serves a dual function: it simultaneously removes visible tumour and provides tissue for histopathological analysis. The pathology report determines the stage (depth of invasion) and grade (aggressiveness) of the cancer, which are the two most critical factors guiding all subsequent treatment decisions.

Bladder cancer is the 10th most common cancer worldwide, with approximately 570,000 new cases diagnosed each year. About 75% of newly diagnosed cases are non-muscle-invasive bladder cancer (NMIBC) — confined to the inner lining (Ta, T1) or flat high-grade lesion (Tis/CIS) — for which TURBT is the primary and often curative treatment. The remaining 25% present as muscle-invasive bladder cancer (MIBC), where TURBT is still the initial diagnostic step, but definitive treatment requires radical cystectomy or trimodal therapy.

TURBT is one of the most frequently performed urological operations globally, and when performed to a high standard with complete resection and adequate depth sampling, it is the cornerstone of bladder cancer management.

TURBT is indicated for the following bladder conditions:

• Non-muscle-invasive bladder cancer (NMIBC):
  • Stage Ta — Papillary tumour confined to the urothelium. Low-grade Ta is managed with TURBT alone with close surveillance. High-grade Ta typically requires adjuvant intravesical BCG therapy.
  • Stage T1 — Tumour invades the lamina propria (connective tissue layer beneath the urothelium). High-grade T1 tumours carry a significant risk of progression to muscle-invasive disease and require prompt re-TURBT and aggressive intravesical therapy or early cystectomy consideration.
  • Carcinoma in situ (Tis/CIS) — Flat, high-grade lesion that may not be visually obvious but carries a high risk of progression. Often identified only on biopsy during TURBT or subsequent surveillance cystoscopy.
• Muscle-invasive bladder cancer (MIBC) — staging: TURBT provides the tissue diagnosis and confirms depth of invasion (T2 or beyond), directing the patient towards radical cystectomy, neoadjuvant chemotherapy, or trimodal therapy.
• Bladder papilloma: Benign papillary urothelial lesions with low malignant potential that may be resected during TURBT.
• Haematuria investigation: When haematuria (blood in urine) reveals a suspicious bladder lesion on cystoscopy or imaging, TURBT is used for definitive diagnosis and simultaneous treatment if malignant.

TURBT is appropriate for virtually all patients in whom a bladder tumour has been identified and where the benefits of diagnosis and treatment outweigh surgical risk. Key considerations include:

• Confirmed or suspected bladder tumour: Any papillary or flat lesion identified on cystoscopy or cross-sectional imaging (CT urogram) should proceed to TURBT unless the patient's overall condition makes anaesthesia unsafe.
• Fitness for anaesthesia: TURBT is performed under spinal or general anaesthesia. Most patients with bladder cancer are older adults with comorbidities. Pre-operative cardiac and respiratory assessment is standard. Spinal anaesthesia is often preferred in elderly patients with pulmonary comorbidities as it avoids the obturator nerve reflex seen with general anaesthesia during lateral wall tumour resection.
• Anticoagulation management: Patients on antiplatelet agents or anticoagulants must have their medication adjusted pre-operatively in consultation with their cardiologist or haematologist to minimise bleeding risk. In urgent cases where the benefit outweighs risk, TURBT may proceed with modified technique.
• Re-TURBT candidacy: International guidelines (EAU, AUA/SUO) recommend repeat TURBT 4–6 weeks after the initial procedure for high-grade T1 tumours, any tumour where muscularis propria (detrusor muscle) is absent from the specimen, and all T1 tumours. Re-TURBT upstages approximately 25–30% of T1 tumours to muscle-invasive disease.

There are very few absolute contraindications to TURBT, as it is typically an urgent cancer treatment. Relative contraindications include severe coagulopathy, active urinary tract infection (must be treated first), and untreated high-grade cardiac instability.

TURBT is a stepwise procedure performed under direct visual guidance through a resectoscope:

1. Pre-operative preparation: Urine culture to exclude infection, pre-operative blood tests including coagulation profile, consent counselling including risk of obturator nerve reflex during lateral wall resection. Antibiotic prophylaxis (typically a single dose of fluoroquinolone or gentamicin) is administered before the procedure.
2. Positioning and instrumentation: The patient is placed in the lithotomy position. A rigid resectoscope (22–26 Fr) is introduced transurethrally under continuous irrigation with glycine or saline solution to maintain a clear operative field and distend the bladder.
3. Systematic cystoscopy: Before resection, the entire bladder is systematically inspected, including the trigone, lateral walls, posterior wall, dome, and bladder neck. The number, size, location, and morphology of all lesions are documented. Suspicious flat red areas may represent CIS and are biopsied.
4. Tumour resection: Using the loop electrode, the tumour is resected in a systematic fashion — the exophytic component first, then the base at the level of the detrusor muscle, and then the surrounding flat mucosa. It is critical that the resection specimen contains detrusor muscle to enable accurate pathological staging. En-bloc resection (using a monopolar or bipolar loop to remove the entire tumour in one piece) is increasingly performed for tumours <3 cm to improve staging accuracy and potentially reduce recurrence.
5. Haemostasis: Bleeding vessels are coagulated under direct vision. Adequate haemostasis is confirmed before the resectoscope is withdrawn.
6. Urethral catheter: A three-way urethral catheter is inserted for continuous bladder irrigation overnight to prevent clot formation and retention. It is typically removed the following morning.
7. Immediate post-operative intravesical chemotherapy (single-dose): For NMIBC, a single instillation of mitomycin C or epirubicin within 24 hours of TURBT (ideally within 6 hours) reduces recurrence risk by approximately 40% in low-risk disease. It is contraindicated if significant bladder perforation is suspected.

TURBT remains the most important procedure in bladder cancer care for several compelling reasons:

• Definitive diagnosis and staging: No other technique provides both tissue for pathological analysis and direct treatment simultaneously. Accurate staging is essential — understaging at initial TURBT occurs in up to 25% of T1 tumours.
• Curative for low-risk NMIBC: Low-grade Ta tumours have a very low risk of progression to invasive disease (<5%). Complete TURBT with surveillance cystoscopy is curative in the majority of these patients.
• Bladder preservation: For high-risk NMIBC, the combination of TURBT and intravesical BCG immunotherapy preserves the native bladder in approximately 70–80% of patients at 5 years, avoiding cystectomy and its associated significant quality-of-life impact.
• Minimal invasiveness: No skin incisions, no external scars, and recovery is measured in days rather than weeks.
• Guides further treatment: Whether the next step is surveillance, intravesical BCG, radical cystectomy, or chemoradiation, the decision depends entirely on the quality of the TURBT specimen and the accuracy of its pathological interpretation.
• Repeated use: TURBT can be performed multiple times throughout a patient's life for recurrent NMIBC without causing significant structural damage to the bladder, provided each resection is performed carefully.

TURBT is a safe procedure but carries the following recognised risks:

• Bleeding (haematuria): The most common complication. Minor post-operative haematuria resolves within 1–3 days. Significant haemorrhage requiring blood transfusion occurs in approximately 2–5% of cases. Patients on anticoagulants are at higher risk.
• Urinary tract infection: Occurs in 3–8% despite antibiotic prophylaxis. Presents with dysuria, fever, and cloudy urine. Treated with a course of appropriate antibiotics.
• Bladder perforation: Occurs in approximately 1–5% of TURBT procedures, most commonly during resection of the lateral walls (obturator nerve reflex causing adductor muscle spasm). Extraperitoneal perforations are managed with urethral catheter drainage alone. Intraperitoneal perforations — through the full thickness of the bladder into the peritoneal cavity — may require open or laparoscopic surgical repair.
• Obturator nerve reflex: Electrocautery current during lateral wall resection can stimulate the obturator nerve, causing sudden adduction of the ipsilateral thigh. This reflex can cause bladder perforation if it occurs during active resection. It is prevented by using neuromuscular blockade under general anaesthesia or careful technique under spinal anaesthesia.
• Urethral stricture: Repeat TURBT procedures carry a small risk of urethral trauma leading to stricture formation over time.
• Tumour understaging or incomplete resection: The greatest oncological risk. Incomplete resection or failure to sample detrusor muscle can lead to false reassurance and inadequate treatment. This is why re-TURBT is mandated for high-risk NMIBC.

Post-TURBT surveillance is lifelong for most patients, as bladder cancer has the highest recurrence rate of any cancer. The surveillance protocol is risk-stratified:

Low-risk NMIBC (single, Ta, low-grade, <3 cm, no CIS):

• Cystoscopy at 3 months after TURBT
• If negative: annual cystoscopy for 5 years, then discharge if stable

Intermediate-risk NMIBC (multifocal, recurrent, or low-grade T1):

• Cystoscopy at 3 months, then every 3–6 months for 2 years, then annually for at least 5 years
• Adjuvant intravesical chemotherapy (mitomycin C instillations) recommended

High-risk NMIBC (high-grade T1, any CIS, high-grade Ta multifocal):

• Re-TURBT mandatory at 4–6 weeks if detrusor muscle absent or high-grade T1
• Intravesical BCG induction course (6 weekly instillations) followed by maintenance BCG (3 weekly instillations at 3, 6, 12, 18, 24, 30, 36 months — SWOG protocol)
• Cystoscopy + urinary cytology at 3 months, then every 3 months for 2 years, then every 6 months for years 3–5, then annually
• CT urogram every 1–2 years to monitor upper urinary tract

Patients with BCG failure (recurrence or persistence of high-grade tumour after adequate BCG) should be offered radical cystectomy. Pembrolizumab (anti-PD-1 immunotherapy) has received FDA approval for BCG-unresponsive, high-risk NMIBC in patients who refuse or are ineligible for cystectomy.

TURBT costs vary substantially by country, health system, complexity, and whether adjuvant intravesical therapy is required:

• United States: TURBT in an outpatient or ambulatory surgical centre typically costs USD 8,000–20,000 including anaesthesia, facility, and surgeon fees. In-patient admission adds USD 3,000–7,000 per day. BCG instillations cost approximately USD 500–1,500 per instillation.
• United Kingdom (NHS): TURBT is provided free at the point of care under the NHS. Private sector costs range from GBP 3,000–6,000 including the procedure and one-night stay.
• India: TURBT at accredited private hospitals typically costs INR 40,000–1,20,000 (approximately USD 500–1,500). International patients find India particularly cost-effective for bladder cancer management including follow-up cystoscopies.
• Thailand and Turkey: TURBT packages at internationally accredited centres typically range from USD 2,000–5,000 all-inclusive, making these popular medical tourism destinations for bladder cancer care.
• Ongoing surveillance costs: Surveillance cystoscopies (every 3–12 months for years) and imaging represent a significant cumulative cost. Bladder cancer has one of the highest total per-patient costs of any cancer due to the lifelong surveillance requirement.

Insurance coverage for TURBT is universal in most developed countries as it is an essential cancer procedure. For medical tourists, all-inclusive packages that include TURBT, hospital stay, pathology reporting, and follow-up consultations are widely available.

TURBT is the mandatory initial procedure for all bladder tumours and has no true substitute for diagnosis. However, the following approaches complement or follow TURBT:

• Enhanced visualisation TURBT techniques:
  • Blue light cystoscopy (photodynamic diagnosis — PDD): Intravesical instillation of hexaminolevulinic acid (HAL) before cystoscopy causes cancer cells to fluoresce pink/red under blue light. Detects 14–25% more CIS lesions and high-grade tumours compared to white light alone. Reduces recurrence rates in NMIBC and is endorsed by international guidelines.
  • Narrow band imaging (NBI): Uses specific light wavelengths to enhance mucosal vascular patterns without a photosensitising drug. Commercially available on most modern cystoscopes.
• En-bloc resection: Increasingly preferred over piecemeal resection for tumours <3 cm. Provides the entire tumour in one specimen, improving pathological accuracy and reducing tumour cell seeding.
• Intravesical BCG immunotherapy: Post-TURBT adjuvant immunotherapy for high-risk NMIBC. BCG reduces recurrence by 30–40% and progression by 25–30% compared to TURBT alone.
• Radical cystectomy: Removal of the entire bladder. The standard of care for MIBC and high-risk NMIBC that fails BCG therapy. Provides definitive oncological control but requires urinary diversion (ileal conduit or neobladder).
• Trimodal therapy (TMT): TURBT followed by concurrent chemotherapy (cisplatin-based) and external beam radiation therapy. A bladder-preserving option for selected MIBC patients who decline or are unfit for cystectomy. Complete response achieved in 70–80%, with long-term bladder preservation in approximately 50% of responders.
• Systemic immunotherapy: Pembrolizumab and other checkpoint inhibitors are approved for BCG-unresponsive high-risk NMIBC and advanced/metastatic bladder cancer.